

# Influenza Immunization Protocol for Fluzone® Quadrivalent

<b>Purpose</b>	Provide information and guidance for the Influenza Immunization Program in Nunavut.
<b>Objective</b>	To reduce morbidity and mortality secondary to Influenza infection.
<b>Indication</b>	Annual immunization against influenza caused by the specific strains of the influenza virus contained in the vaccine.
<b>Eligibility</b>	Age 6 months and older.
<b>Product</b>	FLUZONE® Quadrivalent (QIV)
<b>Vaccine type</b>	Quadrivalent Inactivated – split virus (for more information see references)
<b>Vaccine components</b>	<p><b>Active Ingredients:</b> Each 0.5 mL dose contains 15 mcg haemagglutinin of each Influenza Virus Type A (H1N1), Type A (H3N2), Type B (Victoria) and Type B (Yamagata) strains.</p> <p><b>Non-medicinal Ingredients:</b> ≤100 µg formaldehyde, up to 0.5 mL sodium phosphate buffered, isotonic sodium chloride solution and ≤250 µg Triton® X-100, 0.01% w/v thimerosal in multidose presentation only (25 µg mercury/0.5 mL dose).<sup>1</sup></p>
<b>Formats available</b>	Multidose vials (5mL), 10 x 0.5 mL doses per vial
<b>Manufacturer</b>	Sanofi Pasteur Limited
<b>Administration</b>	<p><u>Infants &lt;1 year of age:</u> Intramuscular (IM) in the anterolateral thigh (vastus lateralis)</p> <p><u>Children &gt;1 year with adequate muscle mass and adults:</u> Intramuscular (IM) in the deltoid muscle</p>
<b>Dose Series</b>	1 dose of 0.5 mL given via the Intramuscular (IM) route. Vaccine is given annually to anyone age 6 months and older.
<b>Booster Dose</b>	<p><u>Children 6 months to less than 9 years</u> who have never had influenza vaccine should receive 2 doses of 0.5 mL, given at a minimum of 4 weeks apart.</p> <p><b>Note:</b> only one dose of flu vaccine is recommended for children aged 6 months to less than 9 years of age who have received any flu vaccine in past seasons.</p>
<b>Vaccine interchangeability</b>	Individuals aged 65 and older are eligible to receive Fluzone® High-Dose Quadrivalent.

<p><b>Concomitant Administration</b></p>	<p>Fluzone® Quadrivalent may be given at the same time as other inactivated or live vaccines. <b>NACI has determined that COVID-19 vaccines may be administered at the same time as, or at any time before or after, non-COVID-19 vaccines, including Quadrivalent Influenza Vaccine.</b><sup>3</sup> Please take the opportunity to review COVID-19 immunization history and offer immunization to eligible individuals.</p> <p>Additionally, unimmunized adults over 50 years old who have not received pneumococcal polysaccharide vaccine (Pneumovax 23) should be offered this vaccine.</p>
<p><b>Contraindications</b></p>	<p>Age less than 6 months old.</p> <p>FLUZONE® should not be administered to people who have had an anaphylactic reaction to a specific influenza immunization, or to any of the components of a specific influenza vaccine. Egg allergies are not a contraindication.</p> <p>For an apparent allergic reaction to the vaccine or any other symptoms (e.g. throat constriction, difficulty swallowing) that raise concern regarding the safety of re- immunization - please consult the RCDC for guidance.</p> <p>Severe lower respiratory symptoms (wheeze, chest tightness, difficulty breathing) within 24 hours prior to influenza vaccine.</p> <p>Serious acute febrile illness: Persons with serious acute febrile illness usually should not be vaccinated until their symptoms have abated. Those with mild non-serious febrile illness (such as mild upper respiratory tract infections) may be given influenza vaccine.</p> <p>Guillain-Barré syndrome (GBS) within 6 weeks of a previous influenza vaccine.</p>
<p><b>Precautions and Additional Notes</b></p>	<p>The National Advisory Committee on Immunization (NACI) has concluded that egg allergic individuals may be vaccinated against influenza using Fluzone Quadrivalent Influenza Vaccine without a prior influenza vaccine skin test and with the full dose in any setting where vaccines are routinely administered.<sup>2</sup></p> <p>Do not draw up vaccine until ready to administer.</p> <p>NACI states that influenza vaccination is recommended for pregnant women.</p> <p>NACI states that influenza vaccination is considered safe for breastfeeding women.</p>
<p><b>Vaccine Supply and Distribution</b></p>	<p>Review section on vaccine ordering in the Policy and Procedure section of the Nunavut Drug Formulary.</p>
<p><b>Storage</b></p>	<p>Store in monitored vaccine refrigerator between 2°C and 8°C. Keep in original packaging. Protect from light.</p> <p>DO NOT FREEZE. Freezing destroys the active components of the vaccine.</p>

	<p>Follow cold chain protocol and inform RCDC and regional pharmacy for guidance if a cold chain break occurs.</p> <p>Vial may be used up to the date of expiry indicated on the vial label. No need to discard the vial after 28 days of opening/puncturing if stored between 2°C and 8°C.</p>
<b>Consent</b>	Informed verbal consent must be obtained from the client or parent/guardian and appropriately documented in Meditech prior to vaccination.
<b>Anaphylaxis</b>	Review the principles of the emergency management of anaphylaxis in the Nunavut Immunization Manual Section 3 (3.7). Further information can be found in: <a href="#">Anaphylaxis: Initial Management in Non-Hospital Settings</a> , in the Canadian Immunization Guide.
<b>Side Effects</b>	<u>Injection site</u> : pain, tenderness, redness, swelling at injection site. <u>Systemic</u> : fever, fatigue, headache, malaise, and myalgia.
<b>Reportable Adverse Events/Side Effects</b>	Report all serious adverse events requiring medical attention, unusual/unexpected events, or medication errors to RCDC. <a href="#">Review section 3.5 Management and Reporting of Adverse Events in the Nunavut Immunization Manual.</a>
<b>Documentation</b>	<p>All immunizations given should be documented in the electronic record.</p> <p>For children &lt;9 years of age: the first 2 doses of influenza vaccine should also be documented on the Nunavut Immunization Record.</p> <p>Update recipient's Personal Immunization Record as requested</p>
<b>Materials and Resources</b>	<p>All protocols and materials are available on the Department of Health website (<a href="http://www.gov.nu.ca/health">www.gov.nu.ca/health</a>)</p> <p>Nunavut Communicable Disease and Surveillance Manual: Influenza Public Health Protocol</p> <p>Nunavut Immunization Manual</p> <p>Fluzone Quadrivalent Fact Sheet</p>
<b>References</b>	<ol style="list-style-type: none"> <li>1. FLUZONE® Quadrivalent. Product Monograph. Sanofi Pasteur. April 2022. Available at <a href="http://fluzone-qiv.sanofi.ca">fluzone-qiv (sanofi.ca)</a></li> <li>2. Public Health Agency of Canada. Canadian Immunization Guide. Available at: <a href="http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php">http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php</a></li> <li>3. <a href="#">National Advisory Committee on Immunization (NACI) statement: Seasonal influenza vaccine for 2023-2024 - Canada.ca</a></li> </ol>